Skip to main content

Table 4 Injection site reactions in 20 patients who received at least one vaccination

From: HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

Injection sites Number (%)
Swelling
<4 0 (0%)
4-8 13 (65%)
>8 7 (35%)
Erythema
mild 4 (20%)
moderate 16 (80%)
severe 0 (0%)
Temp
mild 4 (20%)
moderate 15 (75%)
severe 1 (5%)
Pain
mild 17 (85%)
moderate 3 (15%)
severe 0 (0%)
Itching
mild 17 (85%)
moderate 3 (15%)
severe 0 (0%)
Ulceration 0 (0%)
  1. All the injection sites were scored 1 hour after administration of the vaccine. The pain and itching is scored at the following visit (i.e. 3 weeks after the vaccination by using the diary). Only the maximal injection site reaction per patient is scored.